AGEN Agenus Inc.
$6.65▲ +7.95%
Healthcare
Other
After hours
$6.65▲ +0.00%
Oct 27, 4:17 PM ET
Volume 839.0K
Avg Volume (10D) 791.6K
Key Metrics & Fundamentals
Market Cap
$300.33M
P/E Ratio
2.7
Div Yield
0.00%
52W Range
2.71 - 10.31
% vs 50 MA
-12.88%
% vs 200 MA
35.94%
RSI-14
44.2
MACD Histogram
-0.0700
Beta (1Y vs SPY)
1.46
Free Cash Flow
-$31.20M
Gross Rev
$34.52M
Gross Profit
$19.76M
EBITDA
$15.19M
COGS
$14.76M
Operating Exp
$8.47M
Operating Income
$11.29M
EBIT
$11.29M
Pretax Income
-$567,000
Net Income
-$550,000
EPS (Diluted)
-0.01
Price & Volume History
Loading chart…
Recent News
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Business Wire · Oct 25, 2026 7:00 AM ET
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Business Wire · Oct 22, 2026 4:30 PM ET
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
MarketBeat · Oct 20, 2026 5:02 PM ET
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Business Wire · Oct 9, 2026 3:23 PM ET
Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
MT Newswires · Oct 8, 2026 8:01 AM ET
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Business Wire · Oct 8, 2026 7:30 AM ET
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Business Wire · Oct 3, 2026 10:50 AM ET
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Business Wire · Oct 2, 2026 9:00 AM ET
Agenus Shares Rise After Chardan Initiates Coverage at Buy
MT Newswires · Sep 28, 2026 3:01 PM ET
Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing
Simply Wall St. · Sep 19, 2026 10:09 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AGEN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.